ID   YUSIT1-B5
AC   CVCL_R738
DR   cancercelllines; CVCL_R738
DR   Cosmic; 1921230
DR   Wikidata; Q54995805
RX   Patent=US20130231347;
RX   PubMed=22389471;
CC   Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; GSK2118436).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Not specified.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A747 ! YUSIT1
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 05-10-23; Version: 14
//
RX   Patent=US20130231347;
RA   Bleam M.R., Gilmer T.M., Greger J.G., Laquerre S.G., Liu L.;
RT   "Method of treatment with BRAF inhibitor.";
RL   Patent number US20130231347, 05-Sep-2013.
//
RX   PubMed=22389471; DOI=10.1158/1535-7163.MCT-11-0989;
RA   Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M.,
RA   Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M.;
RT   "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired
RT   resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by
RT   NRAS or MEK mutations.";
RL   Mol. Cancer Ther. 11:909-920(2012).
//